Provided by Tiger Fintech (Singapore) Pte. Ltd.

SIMCERE PHARMA

7.300
-1.360-15.70%
Volume:12.44M
Turnover:93.79M
Market Cap:18.15B
PE:23.60
High:8.030
Open:8.000
Low:7.180
Close:8.660
Loading ...

Simcere Pharmaceutical Posts 2.6% Profit Increase in 2024; EPS, Revenue Miss Estimates; Shares Down 3%

MT Newswires Live
·
25 Mar

Simcere Pharmaceutical - Declared the Payment of Final Dividend of RMB0.16 per Share

THOMSON REUTERS
·
24 Mar

Simcere Pharmaceutical Group FY Net Income RMB 733 Million

THOMSON REUTERS
·
24 Mar

Simcere Pharmaceutical Group Gets NDA for Anti-Influenza from NMPA

MT Newswires Live
·
17 Mar

BRIEF-Simcere Pharmaceutical Says NDA Of Deunoxavir Marboxil Tablets Accepted By NMPA

Reuters
·
17 Mar

Simcere Pharmaceutical - New Drug Application (Nda) of Deunoxavir Marboxil Tablets Was Accepted by Nmpa

THOMSON REUTERS
·
17 Mar

Simcere Pharmaceutical Group Limited's (HKG:2096) Price In Tune With Revenues

Simply Wall St.
·
07 Mar

Simcere Pharmaceutical Forecasts Slight Increase in 2024 Profit

MT Newswires Live
·
21 Feb

Fermion and Simcere Enter Into an Exclusive License and Collaboration Agreement for China's First Sstr4 Agonist Targeting Pain

THOMSON REUTERS
·
18 Jan

BRIEF-Simcere Pharmaceutical Says Option To License Agreement Of Sim0500 With Abbvie

Reuters
·
13 Jan

China's Simcere Pharma grants AbbVie option to license its blood cancer drug candidate

Reuters
·
13 Jan

Simcere Zaiming and Abbvie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

THOMSON REUTERS
·
13 Jan

Abbvie Inc - Simcere Zaiming to Receive up to $1.055B in Payments From Abbvie

THOMSON REUTERS
·
13 Jan

Abbvie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

THOMSON REUTERS
·
13 Jan

Abbvie Inc - Eligible to Receive Tiered Royalties on Sales in Greater China

THOMSON REUTERS
·
13 Jan

Simcere Pharmaceutical - - Option to License Agreement of Sim0500 With Abbvie for Rights Outside Greater China

THOMSON REUTERS
·
13 Jan

Simcere Pharmaceutical- Under Deal Co to Receive Upfront Payment From Abbvie, Eligible to Receive Option Fees & Milestone Payments of up to $1.055 Bln

THOMSON REUTERS
·
13 Jan

Simcere Pharma Gets Clinical Trial Nod in China for Anti-Tumor Drug

MT Newswires Live
·
06 Jan

BRIEF-Simcere Pharmaceutical Says Clinical Trial Approval For SIM0505 Issued By NMPA

Reuters
·
06 Jan

Simcere Pharmaceutical - Clinical Trial Approval for Sim0505 Issued by Nmpa

THOMSON REUTERS
·
06 Jan